Diversity and Equity Are Critical to the Work We Do
Systemic racism is as real as any disease.
The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.
Our Continued Commitment to Industry Change
We’re working with patients, community groups and policymakers to address
social determinants of health and to drive proactive research that expands
data collection and improves health outcomes.
Clinical Trial Diversity
We’re committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.
We aim to grow the talent pool, create new pathways to our industry and foster more inclusive work environments so that our workforce better reflects census representation top to bottom and side to side.
Voices from Our Catalyst Blog
PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in DC-based, Black-owned newspapers the Informer and the AfroAmerican. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…
“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.
I urge you to follow the progress at PhRMA.org/Equity.”